Neo Ivy Capital Management Ultragenyx Pharmaceutical Inc. Transaction History

Neo Ivy Capital Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 24, 2023	BUY	$33.72 - $46.33 $102,980 - $141,491	3,054 New	3,054 $141,000
Q4 2021 Feb 15, 2022	SELL	$73.71 - $87.86 $284,815 - $339,491	-3,864 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$77.92 - $102.4 $301,082 - $395,673	3,864 New	3,864 $302,000
Q2 2020 Aug 17, 2020	SELL	$46.91 - $78.22 $181,260 - $302,242	-3,864 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$46.91 - $78.22 $181,260 - $302,242	3,864 New	3,864 $302,000

325

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.